Guggenheim reiterated a Buy rating and $80.00 price target on Teva Pharma (NYSE: TEVA) following the close of the company's ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE